Persons living with HIV (PLHIV) who received monthly long-acting (LA) intramuscular formulations of the INSTI* cabotegravir and the NNRTI** rilpivirine reported higher levels of treatment satisfaction and treatment acceptance, and greater willingness to continue therapy as opposed to a daily oral antiretroviral therapy (ART) regimen, according to patient-reported outcomes of the ATLAS*** and FLAIR# trials presented at IAS 2019.
Oral solithromycin may not be a suitable substitute for ceftriaxone plus azithromycin in the first-line treatment of uncomplicated genital gonorrhoea, according to results of the phase III SOLITAIRE-U* trial.
The University of Cambridge, the Royal College of Physicians, London (RCP) and the Sunway Group have launched a collaborative continuing medical education (CME) seminar series for Malaysian healthcare professionals.
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A 3-day course of pivmecillinam to treat uncomplicated lower urinary tract infection (UTI) yielded similar outcomes as a 5-day course, suggesting that 3-day treatment may be sufficient, according to a study from Denmark.
A recently published analysis of the world’s largest genome-wide association study (GWAS) of lung cancer among female never-smokers found a set of tuberculosis (TB)-related genes associated with lung adenocarcinoma in Asian women.
Human papillomavirus (HPV) vaccination significantly reduces the frequency of genital HPV 16 and 18 infections and cervical intraepithelial neoplasia grade 2+ (CIN2+) in young women and shows signs of herd effects with a reduced frequency of anogenital warts in both young women and men, a recent study showed.
The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.
Sustained virologic response (SVR) rates with a 12-week course of ribavirin therapy appear to be lower than expected in an Asian cohort of transplant recipients with hepatitis E virus (HEV) infection, with those who received kidney transplant as opposed to other organs being more likely to fail therapy, as reported in a recent study from Singapore.
A quadruple combination antiretroviral therapy (cART) demonstrates similar effects when compared to a triple cART in treatment-naïve people with HIV, according to the results of a systematic review and meta-analysis.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng,
10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.